Stock 6733 BIOGEND THERAPEUTICS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Company BioGend Therapeutics Co., Ltd.

Equities

6733

TW0006733009

Biotechnology & Medical Research

End-of-day quote Taipei Exchange
Other stock markets
 23:00:00 27/05/2024 BST 		5-day change 1st Jan Change
36.15 TWD -0.96% Intraday chart for BioGend Therapeutics Co., Ltd. -3.60% -5.49%
05-10 BioGend Therapeutics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
03-02 BioGend Therapeutics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Business Summary

BIOGEND THERAPEUTICS CO., LTD. is a medical equipment company mainly engaged in the development of biological aggregate. The Company is mainly engaged in the development and research of high-grade bone filling materials and knee cartilage repair related medical equipment. The Company's main products are BiG-001 which used for long bone biological aggregate, BiG-006 that used for lumbar interbody fusion biological bone, as well as BiG-009.

Sales per Business

TWD in Million2022Weight2023Weight Delta
Orthopedic Medical Devices
100.0 %
31 100.0 % 110 100.0 % +249.51%

Sales per region

TWD in Million2022Weight2023Weight Delta
Taiwan
66.9 %
31 99.0 % 74 66.9 % +136.18%
Japan
22.6 %
0 0.0 % 25 22.6 % +248,700.00%
Others
10.5 %
0 1.0 % 11 10.5 % +3,730.67%

Managers

Managers TitleAgeSince
Te Li Chen CEO
 Chief Executive Officer 55 06/07/16
Tsang Cheng Lin CEO
 Chief Executive Officer - 29/04/18
Shu Wei Chao DFI
 Director of Finance/CFO - -
Liang Yan Wang IRC
 Investor Relations Contact - 31/08/17
Po Chih Chang PRN
 Corporate Officer/Principal - 31/07/17

Members of the board

Members of the board TitleAgeSince
Jung Chin Lin BRD
 Director/Board Member 70 19/05/19
Hai Yi Ma BRD
 Director/Board Member - 19/05/18
Te Li Chen CEO
 Chief Executive Officer 55 06/07/16
Shao Feng Chien BRD
 Director/Board Member - 19/05/18
Tsang Cheng Lin CEO
 Chief Executive Officer - 29/04/18
Hsuan hao Chang BRD
 Director/Board Member - 19/05/18
En Tzu Liu BRD
 Director/Board Member - 19/05/19

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 123,076,000 72,655,026 ( 59.03 %) 0 59.03 %

Company contact information

BioGend Therapeutics Co., Ltd.

4th Floor No.3 Park Street

115 03, Taipei

+

http://www.biogend.com.tw
address BioGend Therapeutics Co., Ltd.(6733)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per region

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
36.15 TWD
Average target price
48 TWD
Spread / Average Target
+32.78%
Consensus

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
BIOGEND THERAPEUTICS CO., LTD. Stock BioGend Therapeutics Co., Ltd.
-5.49% 138M
MODERNA, INC. Stock Moderna, Inc.
+54.05% 58.71B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-2.02% 41.31B
LONZA GROUP AG Stock Lonza Group AG
+37.57% 39.2B
CELLTRION, INC. Stock Celltrion, Inc.
-10.22% 27.4B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.42% 26.55B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.60% 18.98B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+2.89% 12.51B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+22.40% 11.94B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.49% 12.08B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 6733 Stock
  4. Company BioGend Therapeutics Co., Ltd.